Trials / Unknown
UnknownNCT04610541
REMdesivir-HU Clinical Study and Severe Covid-19 Patients
Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,000 (estimated)
- Sponsor
- University of Pecs · Academic / Other
- Sex
- All
- Age
- 12 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 3, open-label, multi-center, interventional safety study of REM therapy in participants 12 years of age or older with COVID-19, pneumonia and oxygen supplementation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remdesivir-HU | Remdesivir-HU 100 mg concentrate for solution for infusion |
Timeline
- Start date
- 2020-10-12
- Primary completion
- 2021-10-30
- Completion
- 2021-11-30
- First posted
- 2020-10-30
- Last updated
- 2020-11-27
Locations
7 sites across 1 country: Hungary
Source: ClinicalTrials.gov record NCT04610541. Inclusion in this directory is not an endorsement.